Cytori Therapeutics Company Profile (NASDAQ:CYTX)

About Cytori Therapeutics

Cytori Therapeutics logoCytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient's own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CYTX
  • CUSIP: 23283K10
Key Metrics:
  • Previous Close: $2.04
  • 50 Day Moving Average: $2.09
  • 200 Day Moving Average: $2.67
  • 52-Week Range: $1.81 - $6.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.19
  • P/E Growth: 0.00
  • Market Cap: $41.80M
  • Outstanding Shares: 20,492,000
  • Beta: 2.53
  • Net Margins: -203.79%
  • Return on Equity: -210.47%
  • Return on Assets: -59.01%
  • Debt-to-Equity Ratio: 0.73%
  • Current Ratio: 2.66%
  • Quick Ratio: 2.21%
Additional Links:
Companies Related to Cytori Therapeutics:

Analyst Ratings

Consensus Ratings for Cytori Therapeutics (NASDAQ:CYTX) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (292.16% upside)

Analysts' Ratings History for Cytori Therapeutics (NASDAQ:CYTX)
DateFirmActionRatingPrice TargetDetails
9/14/2016Maxim GroupReiterated RatingBuy$5.00View Rating Details
6/28/2016Roth CapitalReiterated RatingBuy$11.00View Rating Details
5/12/2015Ascendiant Capital MarketsInitiated CoverageBuy$18.75View Rating Details
4/7/2015LaidlawReiterated RatingBuyView Rating Details
(Data available from 9/26/2014 forward)


Earnings History for Cytori Therapeutics (NASDAQ:CYTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.39)($0.43)$2.50 million$1.10 millionViewN/AView Earnings Details
5/10/2016Q1($0.03)($0.41)$2.05 million$2.90 millionViewListenView Earnings Details
3/3/2016Q4($0.04)($0.03)$1.56 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.04)$5.27 million$2.48 millionViewN/AView Earnings Details
8/6/2015Q215($0.03)($0.06)$2.50 million$1.60 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.07)$2.44 million$0.90 millionViewListenView Earnings Details
3/12/2015Q4 14($0.08)($0.08)$3.10 million$2.47 millionViewN/AView Earnings Details
11/10/2014($0.09)($0.12)ViewN/AView Earnings Details
8/12/2014($0.11)($0.15)ViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.14)$2.87 million$1.03 millionViewN/AView Earnings Details
3/12/2014Q413($0.12)($0.14)$4.37 million$2.71 millionViewN/AView Earnings Details
11/7/2013Q313($0.11)($0.08)$3.17 million$8.70 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.13)($0.16)$2.88 million$6.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.16)($0.11)ViewN/AView Earnings Details
11/8/2012Q312($0.15)($0.19)$2.25 million$1.31 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cytori Therapeutics (NASDAQ:CYTX)
Current Year EPS Consensus Estimate: $-1.29 EPS
Next Year EPS Consensus Estimate: $-0.93 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($7.35)($7.35)($7.35)
Q3 20161($7.05)($7.05)($7.05)
Q4 20161($8.25)($8.25)($8.25)
(Data provided by Zacks Investment Research)


Dividend History for Cytori Therapeutics (NASDAQ:CYTX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Cytori Therapeutics (NASDAQ:CYTX)
Insider Ownership Percentage: 2.60%
Institutional Ownership Percentage: 18.48%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016John David HarrisVPBuy2,500$2.03$5,075.00View SEC Filing  
6/14/2016Gail K NaughtonDirectorBuy1,000$2.10$2,100.00View SEC Filing  
5/13/2016John David HarrisVPBuy2,000$2.71$5,420.00View SEC Filing  
3/9/2016David RickeyDirectorBuy150,000$0.19$28,500.00View SEC Filing  
9/3/2015Tommy G ThompsonDirectorBuy25,449$0.37$9,416.13View SEC Filing  
9/2/2015Jeremy B HaydenVPBuy8,200$0.36$2,952.00View SEC Filing  
8/28/2015David RickeyDirectorBuy56,000$0.31$17,360.00View SEC Filing  
8/28/2015Marc H HedrickCEOBuy11,200$0.31$3,472.00View SEC Filing  
8/27/2015David RickeyDirectorBuy75,000$0.31$23,250.00View SEC Filing  
8/21/2015David RickeyDirectorBuy50,000$0.38$19,000.00View SEC Filing  
8/21/2015Marc H HedrickCEOBuy5,000$0.38$1,900.00View SEC Filing  
8/20/2015Marc H HedrickCEOBuy10,000$0.40$4,000.00View SEC Filing  
8/19/2015David RickeyDirectorBuy48,600$0.39$18,954.00View SEC Filing  
8/19/2015Steven KestenVPBuy6,000$0.39$2,340.00View SEC Filing  
8/18/2015David RickeyDirectorBuy51,400$0.39$20,046.00View SEC Filing  
8/18/2015Marc H HedrickCEOBuy10,000$0.39$3,900.00View SEC Filing  
8/18/2015Tiago GiraoCFOBuy25,000$0.39$9,750.00View SEC Filing  
11/13/2014David RickeyDirectorBuy20,000$0.47$9,400.00View SEC Filing  
11/12/2014David RickeyDirectorBuy200,000$0.39$78,000.00View SEC Filing  
11/12/2014Tiago GiraoCFOBuy60,000$0.39$23,400.00View SEC Filing  
11/11/2014Tiago GiraoCFOBuy15,889$0.39$6,196.71View SEC Filing  
6/5/2014David RickeyDirectorBuy30,000$2.34$70,200.00View SEC Filing  
9/12/2013David RickeyDirectorBuy7,100$2.55$18,105.00View SEC Filing  
9/11/2013David RickeyDirectorBuy2,000$2.58$5,160.00View SEC Filing  
9/9/2013David RickeyDirectorBuy5,000$2.31$11,550.00View SEC Filing  
9/5/2013David RickeyDirectorBuy2,000$2.24$4,480.00View SEC Filing  
9/3/2013David RickeyDirectorBuy7,000$2.14$14,980.00View SEC Filing  
8/30/2013Tommy G ThompsonDirectorBuy5,000$2.14$10,700.00View SEC Filing  
12/19/2012Lloyd H DeanDirectorBuy25,000$2.85$71,250.00View SEC Filing  
12/19/2012Marc H HedrickPresidentBuy10,000$2.85$28,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Cytori Therapeutics (NASDAQ:CYTX)
DateHeadline logoStock Update (NASDAQ:CYTX): Cytori Therapeutics Inc Partner Kerastem Completes Enrollment of US Phase II Trial ... - Smarter Analyst (NASDAQ:CYTX) - September 26 at 9:15 AM logoCytori Partner Kerastem Completes Enrollment of US Phase II Trial for Early Stage Hair Loss (NASDAQ:CYTX) - September 26 at 9:15 AM logoBARDA Increases Cytori Therapeutics' Contract Option (CYTX) - Investopedia (NASDAQ:CYTX) - September 25 at 4:07 PM logoBARDA Increases Cytori Therapeutics’ Contract Option (CYTX) (NASDAQ:CYTX) - September 24 at 9:13 AM logoETF’s with exposure to Cytori Therapeutics, Inc. : September 23, 2016 (NASDAQ:CYTX) - September 23 at 4:20 PM
News IconAnalysts gives Consensus Recommendation of “Strong Buy” to Cytori Therapeutics Inc (NASDAQ:CYTX) - DailyQuint (NASDAQ:CYTX) - September 21 at 8:51 AM
News IconPenny Stock Investors Take an Interest in Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Duncan Research (NASDAQ:CYTX) - September 21 at 8:51 AM logoCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex (NASDAQ:CYTX) - September 20 at 8:12 AM logoStock Update (NASDAQ:CYTX): Cytori Therapeutics Inc Announces Increase of Contract Option with BARDA to ... - Smarter Analyst (NASDAQ:CYTX) - September 19 at 9:12 AM logoBARDA Increases Contract Option with Cytori to Advance Countermeasure Clinical Trial (NASDAQ:CYTX) - September 19 at 9:12 AM
News IconKeen Investors Seek Information on Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Duncan Research (NASDAQ:CYTX) - September 17 at 9:16 AM
News Icon"The Depository Trust & Clearing Corporation" is now available at Fast Market Research (NASDAQ:CYTX) - September 16 at 8:12 AM
News IconKeen Investors Narrowing Their Focus on Cytori Therapeutics, Inc. (NASDAQ:CYTX) - Duncan Research (NASDAQ:CYTX) - September 15 at 8:41 AM
News IconCytori Therapeutics Inc. (NASDAQ: CYTX) Buy Rating Reiterated at Maxim Group - BNB Daily (blog) (NASDAQ:CYTX) - September 15 at 8:41 AM logoMaxim Remains Positive on Cytori Therapeutics Inc (CYTX) Following Case Report - Smarter Analyst (NASDAQ:CYTX) - September 14 at 8:43 AM logoCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:CYTX) - September 13 at 9:24 AM logoCase Report Illustrates the Potential Value Cytori Cell Therapy in Treating Chronic Effects of Radiation Damage (NASDAQ:CYTX) - September 12 at 9:27 AM logoCytori to Present in Investor Events in September 2016 (NASDAQ:CYTX) - September 1 at 4:27 PM logoCytori Therapeutics Inc (NASDAQ:CYTX) Is Expected To Post EPS Of $-0.55 - (NASDAQ:CYTX) - August 29 at 4:44 PM logoCytori Therapeutics Receives Frost & Sullivan 2016 Technology Innovation Award (NASDAQ:CYTX) - August 22 at 9:13 AM logoAnalysts See Cytori Therapeutics Inc (NASDAQ:CYTX) Reporting EPS Of $-0.55 - (NASDAQ:CYTX) - August 16 at 6:58 AM logoCYTORI THERAPEUTICS, INC. Financials (NASDAQ:CYTX) - August 13 at 4:31 PM logoETF’s with exposure to Cytori Therapeutics, Inc. : August 11, 2016 (NASDAQ:CYTX) - August 11 at 4:39 PM logoCytori Therapeutics, Inc. :CYTX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:CYTX) - August 9 at 5:36 PM logoCYTORI THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CYTX) - August 5 at 4:36 PM logoCytori Therapeutics Announced Inducement Grant for New Employee (NASDAQ:CYTX) - August 5 at 4:36 PM logoCytori reports 2Q loss (NASDAQ:CYTX) - August 5 at 9:46 AM logoEARNINGS SUMMARY: Details of Cytori Therapeutics Inc. Q2 Earnings Report (NASDAQ:CYTX) - August 4 at 4:46 PM logoEARNINGS SUMMARY: Details of Cytori Therapeutics Inc. Q2 Earnings Report (NASDAQ:CYTX) - August 4 at 4:46 PM logoCytori Reports Second Quarter 2016 Business and Financial Results (NASDAQ:CYTX) - August 4 at 4:46 PM logoCytori Reports Second Quarter 2016 Business and Financial Results (NASDAQ:CYTX) - August 4 at 4:46 PM logoQ2 2016 Cytori Therapeutics Inc Earnings Release - 4:15 pm ET (NASDAQ:CYTX) - August 4 at 9:38 AM logoCytori Therapeutics Inc (CYTX) Jumps 5.85% on July 29 - (NASDAQ:CYTX) - July 30 at 9:34 AM logoCytori Therapeutics (NASDAQ:CYTX) decreased -3.55%: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Vodafone ... - KC Register (NASDAQ:CYTX) - July 27 at 10:15 PM logoWhat Do All These Investigator-Initiated Studies Mean to Cytori? (NASDAQ:CYTX) - July 25 at 7:18 AM logoCytori Therapeutics, Inc. (NasdaqCM:CYTX) Fundamental Star Rating Report - CML News (NASDAQ:CYTX) - July 22 at 4:28 PM logoCytori to Webcast Second Quarter Financial Results on August 4 (NASDAQ:CYTX) - July 22 at 8:18 AM logoPremarket Runners: Netflix, Inc. (NASDAQ:NFLX), Cytori Therapeutics Inc. (NASDAQ:CYTX) - Review Fortune (NASDAQ:CYTX) - July 20 at 9:52 AM logoCytori Cell Therapy Phase I Trial Reports Maxillofacial Bone Regeneration (NASDAQ:CYTX) - July 19 at 4:37 PM logoETF’s with exposure to Cytori Therapeutics, Inc. : July 19, 2016 (NASDAQ:CYTX) - July 19 at 12:16 PM logoCytori Therapeutics Inc (CYTX) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:CYTX) - July 19 at 10:39 AM logoCompany Update (NASDAQ:CYTX): Cytori Therapeutics Inc Cell Therapy™ Phase I Trial Reports Maxillofacial Bone ... - Smarter Analyst (NASDAQ:CYTX) - July 19 at 10:39 AM logo7:02 am Cytori Therapeutics announces the publication of the results from a Phase I trial using Cytori Cell Therapy in patients with insufficient maxillary bone prior to dental implantation (NASDAQ:CYTX) - July 19 at 7:02 AM logoCytori Cell Therapy™ Phase I Trial Reports Maxillofacial Bone Regeneration (NASDAQ:CYTX) - July 19 at 7:00 AM
News IconShares Experiencing a Downtrend: Cytori Therapeutics, Inc. (NASDAQ:CYTX) - TGP (NASDAQ:CYTX) - July 16 at 5:27 AM
News IconHow Analysts Feel About Cytori Therapeutics Inc (NASDAQ:CYTX)? - Press Telegraph (NASDAQ:CYTX) - July 15 at 3:33 PM
News IconSabby Management LLC Decreased Stake in Cytori Therapeutics INC (NASDAQ:CYTX) by $9.84 Million as Shares ... - Press Telegraph (NASDAQ:CYTX) - July 14 at 10:03 PM logoCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and (NASDAQ:CYTX) - July 14 at 5:26 PM logoCytori Therapeutics Inc Stock Momentum Hits Extreme Weakness - CML News (NASDAQ:CYTX) - July 14 at 7:17 AM
News IconCytori Therapeutics DE (NASDAQ:CYTX) Shorted Shares Increased By 58.61% - Consumer Eagle (NASDAQ:CYTX) - July 14 at 7:17 AM


Cytori Therapeutics (NASDAQ:CYTX) Chart for Monday, September, 26, 2016

Last Updated on 9/26/2016 by Staff